Click on the protein name for more information about the protein.
The Score column is the predicted score of interaction between the two proteins
Click on the Evidence link to view a breakdown of the information about the predicted interaction.
| Key | |
|---|---|
| Module Score | Databases |
 | Where interaction is observed in another database a link is provided: |
| Protein 1 (?) | Protein 2 (?) | Name of Protein 2 | Module Scores (?) | Scores (?) | Evidence (?) | Database (?) | |||
|---|---|---|---|---|---|---|---|---|---|
 |  |  |  | ||||||
| PLD2 | RAC2 | RAC2: Ras-related C3 botulinum toxin substrate 2 precursor | 4.10E3 | Evidence | |||||
| PLD2 | ACTG1 | ACTB: Actin, cytoplasmic 1 | 136.0 | Evidence |
|
||||
| PLD2 | PKN2 | PKN2, PRK2, PRKCL2: Serine/threonine-protein kinase N2 | 71.10 | Evidence | |||||
| PLD2 | PRKCG | PRKCG, PKCG: Protein kinase C gamma type | 40.50 | Evidence | |||||
| PLD2 | GSK3A | GSK3A: Glycogen synthase kinase-3 alpha | 32.80 | Evidence | |||||
| PLD2 | JAK2 | JAK2: Tyrosine-protein kinase JAK2 | 31.20 | Evidence | |||||
| PLD2 | PLCB3 | PLCB3: 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase beta-3 | 26.00 | Evidence | |||||
| PLD2 | MAPKAPK5 | N/A | 22.90 | Evidence | |||||
| PLD2 | ZAP70 | ZAP70: Uncharacterized protein ZAP70 | 22.20 | Evidence | |||||
| PLD2 | PLCG1 | PLCG1, PLC1: 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase gamma-1 | 21.10 | Evidence | |||||
| PLD2 | FLT1 | FLT1, FLT, FRT: Vascular endothelial growth factor receptor 1 precursor | 20.50 | Evidence | |||||
| PLD2 | PRKCE | PRKCE, PKCE: Protein kinase C epsilon type | 20.40 | Evidence | |||||
| PLD2 | ACTB | ACTG1, ACTB, ACTG: Actin, cytoplasmic 2 | 19.10 | Evidence | |||||
| PLD2 | CCT2 | CCT2, 99D8.1, CCTB: T-complex protein 1 subunit beta | 18.90 | Evidence | |||||
| PLD2 | ACTR3 | ACTR3, ARP3: Actin-related protein 3 | 18.90 | Evidence | |||||
| PLD2 | MPP6 | MPP6, VAM1: MAGUK p55 subfamily member 6 | 17.10 | Evidence | |||||
| PLD2 | NCF1 | Neutrophil cytosolic factor 1 variant (Fragment) | 17.10 | Evidence | |||||
| PLD2 | KIT | KIT: Mast/stem cell growth factor receptor precursor | 16.60 | Evidence | |||||
| PLD2 | PDGFRB | PDGFRB: Beta-type platelet-derived growth factor receptor precursor | 16.60 | Evidence | |||||
| PLD2 | FER1L3 | FER1L3, KIAA1207, MYOF: Myoferlin | 15.70 | Evidence | |||||
| PLD2 | LYN | LYN: Tyrosine-protein kinase Lyn | 15.30 | Evidence | |||||
| PLD2 | HCK | N/A | 15.30 | Evidence | |||||
| PLD2 | STK10 | STK10: Uncharacterized protein STK10 | 15.30 | Evidence | |||||
| PLD2 | SPTAN1 | N/A | 15.00 | Evidence | |||||
| PLD2 | CSF1R | CSF1R, FMS: Macrophage colony-stimulating factor 1 receptor precursor | 14.60 | Evidence | |||||
| PLD2 | SH2D2A | SH2D2A, SCAP, TSAD, VRAP: SH2 domain-containing protein 2A | 13.80 | Evidence | |||||
| PLD2 | PLD1 | PLD1: Phospholipase D1 | 12.00 | Evidence | |||||
| PLD2 | ERBB3 | ERBB3, HER3: Receptor tyrosine-protein kinase erbB-3 precursor | 11.60 | Evidence | |||||
| PLD2 | CNN2 | CNN2: Calponin-2 | 10.30 | Evidence | |||||
| PLD2 | DGKD | DGKD, KIAA0145: Diacylglycerol kinase delta | 10.30 | Evidence | |||||
| PLD2 | FGR | FGR, SRC2: Proto-oncogene tyrosine-protein kinase FGR | 10.00 | Evidence | |||||
| PLD2 | VAV1 | VAV1, VAV: Proto-oncogene vav | 10.00 | Evidence | |||||
| PLD2 | CSK | CSK: Tyrosine-protein kinase CSK | 10.00 | Evidence |
|
||||
| PLD2 | ARF4 | ARF4, ARF2: ADP-ribosylation factor 4 | 9.02 | Evidence | |||||
| PLD2 | ERBB2 | ERBB2, HER2, NEU, NGL: Receptor tyrosine-protein kinase erbB-2 precursor | 8.7 | Evidence | |||||
| PLD2 | RAC3 | RAC3: Ras-related C3 botulinum toxin substrate 3 precursor | 8.58 | Evidence | |||||
| PLD2 | VIL2 | N/A | 7.73 | Evidence | |||||
| PLD2 | LCP2 | LCP2: Lymphocyte cytosolic protein 2 | 7.40 | Evidence | |||||
| PLD2 | WASPIP | N/A | 6.66 | Evidence | |||||
| PLD2 | WAS | WAS, IMD2: Wiskott-Aldrich syndrome protein | 6.66 | Evidence | |||||
| PLD2 | CCT8 | CCT8: Uncharacterized protein CCT8 | 6.62 | Evidence | |||||
| PLD2 | EEF1A1 | EEF1A1: Elongation factor 1-alpha | 6.62 | Evidence | |||||
| PLD2 | ACTA2 | ACTA2, ACTSA, GIG46, ACTVS: Actin, aortic smooth muscle | 6.54 | Evidence | |||||
| PLD2 | ARF3 | ARF3: ADP-ribosylation factor 3 | 5.83 | Evidence | |||||
| PLD2 | SSH1 | SSH1, KIAA1298, SSH1L: Protein phosphatase Slingshot homolog 1 | 5.74 | Evidence | |||||
| PLD2 | GSN | GSN: Gelsolin precursor | 5.73 | Evidence | |||||
| PLD2 | CFL2 | CFL2: Cofilin-2 | 5.73 | Evidence | |||||
| PLD2 | BCAR1 | BCAR1, CAS, CRKAS: Breast cancer anti-estrogen resistance protein 1 | 5.50 | Evidence | |||||
| PLD2 | SSH2 | SSH2, KIAA1725, SSH2L: Protein phosphatase Slingshot homolog 2 | 4.97 | Evidence | |||||
| PLD2 | GNA12 | GNA12: Guanine nucleotide-binding protein alpha-12 subunit | 4.84 | Evidence | |||||
| PLD2 | ALOX5 | ALOX5, LOG5: Arachidonate 5-lipoxygenase | 4.77 | Evidence | |||||
| PLD2 | TMSL8 | TMSL8, TMSNB: NB thymosin beta | 4.77 | Evidence | |||||
| PLD2 | PFN1 | PFN1: Profilin-1 | 4.62 | Evidence | |||||
| PLD2 | DSTN | DSTN, ACTDP, DSN: Destrin | 4.28 | Evidence | |||||
| PLD2 | CFL1 | CFL1, CFL: Cofilin-1 | 4.28 | Evidence | |||||
| PLD2 | RAC1 | N/A | 3.47 | Evidence | |||||
| PLD2 | CASP3 | CASP3, CPP32: Caspase-3 precursor | 3.47 | Evidence | |||||
| PLD2 | CCT4 | CCT4, CCTD, SRB: T-complex protein 1 subunit delta | 3.20 | Evidence | |||||
| PLD2 | GAPD | GAPDH, GAPD, CDABP0047, OK/SW-cl.12: Glyceraldehyde-3-phosphate dehydrogenase | 3.20 | Evidence |
|
||||
| PLD2 | FLII | FLII, FLIL: Protein flightless-1 homolog | 3.20 | Evidence | |||||
| PLD2 | S100A11 | MLN70, S100A11, S100C: Protein S100-A11 | 2.89 | Evidence | |||||
| PLD2 | ARPC1B | ARC41, ARPC1B: Actin-related protein 2/3 complex subunit 1B | 2.70 | Evidence | |||||
- 
-